Xortx Therapeutics Inc. XRTX shares are trading higher Friday on unusually heavy trading volume. Here's a look at what's going on:
What To Know:
Shares of XRTX are trending on Yahoo Finance and moving on remarkably heavy trading volume Friday, despite a lack of company-specific news.
According to data from Benzinga Pro, more than 45 million shares have already been traded in the session, compared to the stock's 100-day average of just over 200 thousand shares.
Xortx Therapeutics is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection.
Related News: What's Going On With Bitcoin Mining Stocks Marathon Digital And Riot Platforms?
XRTX Price Action: According to Benzinga Pro, Xortx Therapeutics shares are up 52% at 53 cents at the time of publication.
Image: Ri Butov from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.